Abstract. Oral carcinoma is a serious public health problem and the leading cause of head and neck cancer mortality worldwide. Moreover, oral cancer patients often present symptoms at a late stage and show a high recurrence rate after treatment. Therefore, there is an urgent need to identify novel biomarkers for early diagnosis or clinical oral cancer therapy. In this study, we employed a subset of lentiviral short hairpin RNAs targeted against various kinases and phosphatases, designed by The RNAi Consortium, to screen systemically and in a high-throughput manner for potential growth regulators of oral cancer cells. The screen revealed a total of 50 candidate genes, for which more than 90% of growth inhibition in human oral squamous cancer HSC-3 cells was obtained. Furthermore, bioinformatic analysis of these candidate genes identified transforming growth factor-β receptor type II-and fms-related tyrosine kinase 3-related molecular pathways that are involved in NF-κB-mediated growth of HSC-3 cells. These candidate genes may be potential biomarkers for early diagnosis of oral cancer. In addition, these candidate genes represent potential targets for anticancer drug design helping to develop a personalized treatment to combat oral cancer.
Introduction
Head and neck cancer is the sixth most common type of cancer in the world. It arises from epithelial malignancies originating in paranasal sinuses, nasal cavity, oral cavity, pharynx, and larynx (1) . Among these malignancies, oral squamous cell carcinoma (OSCC) is the most prevalent diagnosed malignancy and the leading cause of head and neck cancer death worldwide (2) . Several risk factors for OSCC, including smoking, alcohol drinking, betel quid consumption, human papillomavirus infection, and genetic factors have been reported and well studied for many years (3) (4) (5) (6) (7) (8) . The early clinical diagnosis of OSCC is mainly based on screening for leukoplakia on oral cavity examination. If a precancerous lesion is present, it will subsequently be histologically classified as slight, moderate, or severe hyperplasia, or carcinoma in situ. A higher degree of dysplasia often correlates with a higher possibility that a lesion transforms into a malignant tumor (9) . However, a number of studies suggest that this prediction criterion is not reliable enough; in particular, early genetic changes may not necessarily result in observable changes in morphology (10) (11) (12) . Therefore, identifying novel biomarkers for early diagnosis of OSCC may open up novel therapeutic strategies and/or improve the efficacy of therapeutic treatment.
It is well known that genetic alterations are the defining features of cancer and disturb the signal transduction network in cancer cells, resulting in inappropriate cellular growth, survival and death (13) . Protein kinases and phosphatases are important regulators of cell signaling pathways by governing reversible phosphorylation. Deregulation of kinase or phosphatase activities by genetic alterations causes malignant transformation. Hence, identification of novel kinases and phosphatases responsible for those aberrant cell behaviors will significantly advance our understanding of human oral oncogenesis, subsequently leading to more effective treatments and novel therapeutic strategies Lentiviral short hairpin RNA screen of human kinases and phosphatases to identify potential biomarkers in oral squamous cancer cells (14, 15) . For example, epidermal growth factor receptor (EGFR) has been identified to be amplified in 31% of OSCC patients and correlates with poor clinical outcome. Targeting of EGFR with either a monoclonal antibody against EGFR or a small-molecule EGFR tyrosine kinase inhibitor has been successfully utilized for therapeutic purposes (16, 17) . Currently, it is believed that personalized treatment is the major cancer therapy strategy in the future. Thus, identification of biomarkers of OSCC, such as kinases and phosphatases, is required to achieve this goal (18) . To identify kinases and phosphatases for early diagnosis or as therapeutic targets for OSCC, we employed 'anti-kinome' and 'anti-phosphatome' lentiviral short hairpin RNA (shRNA) subset to perform high-throughput screening for growth regulators of human OSCC cell line HSC-3. Furthermore, the possible cellular pathways for these OSCC-related regulators were also investigated.
Materials and methods
Cell culture. Human OSCC cell line HSC-3 was obtained from the Japanese Collection of Research Bioresources. HSC-3 cells were cultured in DMEM/F12 medium (Gibco) supplemented with 10% FBS (Hyclone) and maintained at 37˚C in a humidified atmosphere with 5% CO 2 .
Lentivirus-based shRNA high-throughput screening. The VSV-G pseudotyped lentivirus-based human kinase and phosphatase subset (KP subset) was obtained from the National RNAi Core Facility (NRCF) located at the Institute of Molecular Biology/ Genomic Research Center, Academia Sinica (Taipei, Taiwan), supported by the National Research Program for Genomic Medicine Grants of NSC (NSC 97-3112-B-001-016). The lentivirus-based shRNA system from NRCF was adopted from The RNAi Consortium (TRC) (19) . TRC designed mutiple distinct shRNA clones to target each gene, and shRNA oligonucleotides were constructed into lentiviral vector pLKO.1-puro to produce VSV-G pseudotyped lentivirus. The KP subset covered 1236 genes in total, including 737 kinases, 209 phosphatases and 30 genes with dual function. Conversion of relative infection unit (RIU) for HSC-3 cells and lentivirus-based shRNA highthroughput screen were adopted by following the protocol of TRC. In brief, for a single shRNA clone, HSC-3 cells were seeded in DMEM/F12 medium in the day before lentivirus transfection at 3x10 3 cells per well in 96-well plates. After 24 h, medium was removed and replaced with fresh DMEM/F12 medium supplemented with 10 µg/ml polybrene, and then lentivirus was added to cells (MOI=3). Medium was removed 24 h post-infection and cells were washed with DPBS. Subsequently, fresh HSC-3 cells growth medium supplemented with 5 µg/ml puromycin was added. After 48 h, medium was removed and replaced with fresh HSC-3 cells growth medium and Cell Counting Kit-8 solution (CCK-8, Dojindo). The plate was incubated for 3 h and then the absorbance at 450 nm was measured. Each shRNA clone infection was performed in duplicate, in two independent 96-well plates. Absorbance values were normalized for each shRNA clone and the average of the duplicates determined to obtain the average percentage of growth inhibition relative to the control.
Bioinformatics analysis. Candidate genes were analyzed using MetaCore™ (GeneGo) as described (20) .
shRNA transfection. Liposome-mediated transfection of shRNA was performed as described (21) . Briefly, cells were seeded the day before shRNA transfection. On the day of transfection, plasmids containing shRNA cassettes and Lipofectamine 2000 (Invitrogen) were separately diluted into Opti-MEM medium (Invitrogen), mixed and incubated for 20 min at room temperature. The resulting lipoplex complex was then added to the cells. After incubation for 6 h, lipoplexes were removed and replaced with fresh DMEM/F12 medium. Cells were harvested for further assays at the indicated time-point.
Viability assay. Cell viability assay was performed using 96-well dish and CCK-8 reagent (Dojindo). Cells were incubated with CCK-8 solution at 37˚C for 3 h after transfection with shRNA or treatment with specific tyrosine kinase inhibitor LY-364947 (Sigma-Aldrich) or Sunitinib malate (BioVision), respectively. Then the absorbance of each well was measured at 450 nm by ELISA reader.
Real-time PCR. Total RNA was isolated 48 h after transfection from HSC-3 cells by using TRIzol reagent (Invitrogen) and converted into cDNA by using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Real-time PCR reactions were performed by using Power SYBR Green Master Mix (Applied Biosystems). Sequences of FLT3 primers (sense: 5'-TCAAGTGCTGTGCATACAATTCCC-3', antisense: 5'-CACCTGTACCATCTGTAGCTGGCT-3') are as previously described (22) . Primers of TGFBR2 (sense: 5'-GGGGAAACAA TACTGGCTGA-3', antisense: 5'-GAGCTCTTGAGGTCCCT GTG-3'), IKBKB (sense: 5'-GCTGCAACTGATGCTG ATGT-3', antisense: 5'-TGTCACAGGGTAGGTGTGGA-3'), SHC1 (sense: 5'-GCCGAGTATGTCGCCTATGT-3', antisense: 5'-GGGTGGGTT-CCTGAGGTATT-3'), SMAD4 (sense: 5'-CCATTTCCAATCATCCTGCT-3', antisense: 5'-ACCT TTGCCTATGTGCAACC-3') and the internal control GAPDH gene (sense: 5'-AATGGAAATCCCATCACCATCTT-3', antisense: 5'-CATCGCCCCACTTGATTTTG-3') were designed using the Primer Express™ software (Applied Biosystems) to specifically amplify the indicated genes. Amplification reactions and data analysis were performed according to the manufacturer's instructions in an ABI PRISM 7900 instrument (Applied Biosystems). The comparative CT method was used for relative quantification of gene expression.
Western blot analysis.
Western blot analysis was conducted as previously described (23) . Monoclonal antibodies against TGFBR2, FLT3, IKBKB, SHC1, phospho-SHC1 (Y317) and SMAD4 were purchased from Abcam, while anti-phospho-IKBKB (S177) was purchased from Cell Signaling Technology. The anti-β-actin monoclonal antibody was purchased from Chemicon. The secondary antibodies horseradish peroxidase (HRP)-linked goat anti-mouse IgG and HRP-linked goat antirabbit IgG were purchased from Santa Cruz Biotechnology and Cell Signaling Technology, respectively.
Immunofluorescence microscopy. To investigate the subcellular localization of nuclear factor-κB (NF-κB), HSC-3 cells were fixed and permeabilized according to the manufacturer's instructions (Invitrogen). Briefly, HSC-3 cells were transfected with indicated shRNA for 48 h, fixed by incubation for 20 min at room temperature in DPBS containing 4% formaldehyde, and then permeabilized by incubation for 20 min on ice in DPBS containing 0.2% Triton X-100. Fixed cells were blocked with 5% bovine serum albumin (Sigma-Aldrich) and incubated with anti-NF-κB monoclonal antibodies (Santa Cruz) for 1 h, followed by incubation with goat anti-rabbit Alexa fluor ® 488 secondary antibody (Invitrogen) for 1 h with washing in between. Finally, cells were stained with 4' ,6-Diamidino-2-phenylindole dihydrochloride (DAPI; Sigma-Aldrich) for 10 min at room temperature. Subcellular localization of NF-κB was observed by using a Leica TCS SP2 confocal microscope (Leica Microsystems).
Biohazard. All experiments involving lentivirus-based shRNA were performed in a P2 Lab under the Institutional Biosafety Guideline.
Statistical analysis. The quality of screening results were determined by using the Z factor (24) . The criteria of potential candidate genes used a Z factor cutoff of >0. All data were analyzed by using the paired Student's t-test for comparison of independent means. P<0.05 (two-tailed) was considered to be significant.
Results
Lentivirus-based shRNA high-throughput screen to identify genes required for growth of oral cancer cells. To identify genes involved in growth regulation of human oral cancer cells, we screened human OSCC cell line HSC-3 by using a lentivirusbased shRNA subset against human kinases and phosphatases. NRCF determined the relative viral titer with regard to the A549 cell line. Because different cell lines might respond differently to VSV-G pseudotyped lentivirus, we converted the RIU from A549 to HSC-3 cells. To this end, we generated a line chart of HSC-3 cell viability versus a serially diluted titer of control shLuc virus and then established a standard curve for lentivirus transfection titer. Next, we converted the RIU for HSC-3 cells and determined the virus titer and MOI according to the standard curve. Then, based on the converted RIU, we adopted the lentivirus-based shRNA high-throughput screening and analyzed the viability of HSC-3 cells after virus infection for 72 h. The preliminary screening results, as shown in Fig. 1 , yielded 50 genes (equivalent to 116 shRNA clones), which were then selected as candidates for further evaluation (~4% hit rate). To recognize potential off-target effects of shRNA, two or more shRNAs for each gene were used. Only genes, for which growth of HSC-3 cells was significantly inhibited (>90%) by at least two shRNA clones with a Z factor >0, were selected as candidates. The information of these candidate shRNA clones are listed in Table Ι . Then, bioinformatics analysis was conducted to study the relationship between these candidate genes.
Bioinformatics analysis reveals potential biomarkers and molecular pathways that are involved in growth of oral cancer.
To further determine the molecular signaling pathways regulating the growth of HSC-3 cells, all candidate genes were subjected to GeneGo MetaCore analysis. Fig. 2A shows the results from the shortest path algorithm of Dijkstra to obtain the closely related signaling molecules (25) . Based on the results of MetaCore analysis, we propose that TGFBR2 and FLT3 regulate the growth of HSC-3 cells through activating SHC1 and IKBKB via phosphorylation followed by activation of their downstream signaling pathways, resulting in NF-κB translocation from cytoplasm to nucleus then transcribing genes that promote growth of HSC-3 cells. According to our results and several other reports (26) (27) (28) , a putative molecular pathway is proposed in Fig. 2B .
Validation of the candidate genes. We then performed the validation for the specificity of candidate shRNAs and the correlations between shRNA-mediated gene knockdown and phenotype of cell growth inhibition. According to the results of the bioinformatics analysis, the major components (i.e., TGFBR2, FLT3, SHC1 and IKBKB) of this putative molecular signaling pathway and some relevant candidate genes (i.e., CBLB, CDKN1A, MAPK14 and SMAD4) were chosen for validation by applying a transient tansfection system to deliver their corresponding shRNAs into HSC-3 cells. First, we examined whether the expression of candidate genes were knocked down by their specific shRNAs. As shown in Fig. 3A and B, all candidate shRNAs were able to suppress both the expression of mRNA and protein of their target genes in HSC-3 cells after 48 h of transfection. Furthermore, based on the results shown in Fig. 3C , we found these candidate shRNAs could also suppress the growth of HSC-3 cells. These results demonstrated the specificity of candidate shRNAs.
Suppression of TGFBR2 and FLT3 downregulates SHC1 and IKBKB resulting in NF-κB translocalization and growth inhibition of HSC-3 cells.
To unravel the putative molecular signaling pathway predicted by bioinformatics analysis, HSC-3 cells were transfected with either TGFBR2 shRNAs (#832 and #833) or FLT3 shRNAs (#9886 and #9888), respectively, and protein expression and phosphorylation level of SHC1 and IKBKB were measured by Western blot analysis (Fig. 4A) . Both protein expression and phosphorylation level of SHC1 and IKBKB were decreased by TGFBR2 or FLT3 shRNAs. Furthermore, subcellular localization of NF-κB was also changed from cytoplasm to nucleus after transfection with either TGFBR2 shRNAs (#832 and #833) or FLT3 shRNAs (#9886 and #9888) for 48 h (Fig. 4B ). In addition, growth inhibition of HSC-3 cells were also observed by using tyrosine kinase antagonists LY-364947 and Sunitinib malate against TGFBR2 and FLT3, respectively. Taken together, these results revealed a putative molecular signaling pathway which regulates the growth of HSC-3 cells.
Discussion
With the advancement of genomics technologies, scientists can now easily study various kinds of human disease followed by their molecular signature (29) . Among these tools, RNAi provides a comprehensive approach to specifically knock down gene function in a high-throughput fashion in mammalian cells (30) . In this study, we used the KP subset to identify potential growth regulators of HSC-3 cells. The screening results identified 50 candidate genes that may be involved in the growth regulation of HSC-3 cells. Inhibition of these candidate genes resulted in significant growth inhibition effect on HSC-3 cells, showing these candidate genes, like oncogenes, may play a role in 'promoting' the growth of OSCC cells. On the other hand, we also identified another group of shRNAs with growth promotion effect on HSC-3 cells (data not shown). These genes, like tumor suppressor genes, may play a role in 'suppressing' the growth of OSCC cells. In order to understand the molecular mechanisms regulating the growth of OSCC cells, both growth promoting and inhibiting groups of genes may be combined for further analyzing how they interact each other to regulate the growth of OSCC cells. The 50 candidate genes were further analyzed by bioinformatics software and revealed a putative molecular signaling pathway regulating the growth of HSC-3 cells. We found that suppression of TGFBR2 or FLT3 expression by specific shRNAs could cause downregulation of protein expression and phosphorylation of SHC1 and IKBKB. Furthermore, suppression of TGFBR2 or FLT3 led to relocalization of transcription factor NF-κB from the cytoplasm to the nucleus. The human FLT3 gene encodes a membrane-bound receptor tyrosine kinase (RTK), which belongs to the RTK subclass III family. FLT3 is known to play a crucial role in both normal haematopoiesis and acute myeloid leukemia (31) . Our results suggest that FLT3 may also be involved in the growth regulation of OSCC cells through regulating IKBKB and NF-κB. To the best of our knowledge, this is the first report showing that FLT3 plays an important role in the growth regulation of OSCC cells. However, the molecular mechanisms how FLT3 regulates IKBKB and NF-κB remain to be further investigated. Nevertheless, small molecule drugs specifically targeting the RTK subclass III family such as FLT3, like Sunitinib, may hold potential for treating OSCC in the future (32) .
The human TGFBR2 gene belongs to the TGF-β superfamily receptors. The role of TGF-β superfamily members (TGF-βs) in carcinogenesis is similar to a double-edged sword. In normal tissues, TGF-βs act as tumor suppressors through SMAD-dependent signaling pathways. However, during carcinogenesis, TGF-βs perform oncogenic activities, either through SMAD-independent, or cooperation between alternative pathways (e.g., aberrant activation of Ras/MAPK signaling pathways) and relatively low activated SMAD pathways (33, 34) . Our results show that suppression of TGFBR2 causes growth inhibition of OSCC cells and decreases the protein expression and phosphorylation levels of SHC1 and IKBKB. Furthermore, suppression of TGFBR2 does lead to translocalization of NF-κB without affecting the subcellular localization of SMAD4 (data not shown). Based on these results, it is reasonable to propose that TGFBR2 may promote the growth of OSCC cells through regulating transcription factor NF-κB.
Among these 50 candidate genes, several genes have been reported to be involved in regulation of apoptosis and chemoresistance in HeLa cervical carcinoma cells (35) . These genes are MAP2K1IP1, PPEF2, PTEN and TGFBR2, which were considered as survival genes. Suppression of expression of these genes induced apoptosis or decreased chemoresistance of cancer cells against anticancer drugs like Taxol. However, our results demonstrate that growth inhibition effect caused by suppression of these genes does not induce apoptosis of HSC-3 cells (data not shown). Despite similar effects of these genes on HeLa and HSC-3 cells are not observed; both studies demonstrate that all these genes may still be important biomarkers of cancer cells.
Although PTEN and CDKN1A are known as tumor suppressors, they were also reported to play a role as positive regulators of cell growth (35) . Interestingly, in our study we found that suppression of PTEN or CDKN1A resulted in growth inhibition of HSC-3 cells. It is possible that PTEN and CDKN1A may be responsible for other functions in growth regulation of tumor cells. For example, Akt-induced phosphorylation of CDKN1A increases the cytoplasmic localiztion and protein stabillity of CDKN1A, resulting in promotion of growth and survival of tumor cells (36, 37) . The molecular mechanism of PTEN and CDKN1A in growth regulation of OSCC cells remains to be clarified.
The current strategy to cancer therapy is often referred to as 'one drug for all'. This leads frequently to inappropriate therapy and causes patients to suffer from side effects of drug toxicity. It is believed that personalized medicine has the potential to improve this problem (18, 38) . In this research, we applied the 'anti-kinome' and 'anti-phosphatome' lentiviral shRNA subset to high-throughput screen and identify the potential biomarkers of OSCC cells. These potential biomarkers and their putative molecular pathways may be used as targets for early diagnosis of the OSCC. Moreover, they may also be beneficial to develop personalized medicine against OSCC.
